Viamet Pharmaceuticals has filed an initial public offering for up to $100 million worth of shares. The North Carolina-based drug maker has researched and developed antifungal drugs. “We have applied our technology to design antifungal compounds that we believe are highly differentiated from, and will address the shortcomings of, currently available antifungal agents,” the company said in a filing Friday. Viamet warned, however, that it has “limited operating history” and has incurred “significant” losses since its start, including a deficit of $86 million as of December. It anticipates it will “continue to incur losses for the foreseeable future,” it said in the filing. The company is expected to trade on the Nasdaq stock exchange under the symbol VMET.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.